Skip to main content

Table 1 Main characteristics of the included studies

From: Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis

Study Year Tumor type No. of Patients Male/Female median age (range) (year) Staining TATE: Present / absent Tumor stage median follow-up date (months) Survival Quality Score (NOS)
Peurala, E. etal [15] 2018 Oral cancer 99 55/44 65.3 H&E 51/47 I - III 40.7 OS 8
Oliveira, D. T. etal [16] 2012 Oral cancer 71 55/16 59 (35, 77) H&E 35/36 I - II NR DFS 7
Tostes Oliveira, D. etal [19] 2009 Oral cancer 43 27/16 55.79 (28, 83) H&E 21/22 I - IV (3, 229) OS 7
Dorta, R. G. etal [17] 2002 Oral cancer 125 105/20 58 (30, 95) H&E 57/68 II - III 88.2 (0, 287.4) OS, DFS 7
Dante, P. etal [40] 2019 Tongue Carcinoma 259 223/36 53.0 ± 12.2 H&E NR I - IV NR OS, DFS 8
Alrawi, S. J. etal [18] 2005 Head and neck carcinoma 87 NR (41, 76) H&E 13/7 II - IV 36 (6, 216) OS, DFS 7
Ercan, I. etal [20] 2005 Laryngeal carcinoma 78 78/0 55.9 (35, 80) H&E 25/53 NR 41.91 OS 7
Sassler, A. M. etal [21] 1995 Laryngeal carcinoma 248 NR NR H&E 56/192 III - IV 48 OS, DFS 6
Thompson, A. C. etal [22] 1994 Laryngeal carcinoma 104 85/19 64.6 (39, 91) H&E 31/73 NR ≥ 60 OS 6
Fujii, M. etal [23] 2002 Nasopharyngeal carcinoma 53 40/13 49.4 (15, 81) H&E 26/27 I - IV 90.5 (35.3, 199.9) DFS 7
Leighton, S. E. etal [24] 1996 Nasopharyngeal carcinoma 96 68/28 NR H&E 65/31 NR 57 OS, DFS 6
Harbaum, L. etal [25] 2015 Colorectal cancer 381 166/215 68.5 H&E 101/280 I - IV 45 (1, 182) OS 8
Fernandez-Acenero, M. J. etal [26] 2000 Colorectal cancer 126 70/56 67.35 (32, 87) H&E 29/97 Duke’s A-C ≥ 60 OS, DFS 8
Nielsen, H.J. etal [27] 1999 Colorectal cancer 584 240/344 61 (49, 75) H&E 150/115 Duke’s A-D 61 (49, 75) OS 7
Prizment, A. E etal [28] 2016 Colorectal cancer 441 0/441 (55, 69) H&E; EPX 197 /244 NR 60 OS 8
Zhang, Y. etal [29] 2014 Esophageal carcinoma 36 25/11 59 (45, 77) H&E 18/18 I - IV 22 (2, 143) OS 7
Ishibashi, S. etal [30] 2006 Esophageal carcinoma 97 82/15 62.7 ± 8.9 H&E 30/31 NR 61.7 (5.3, 165.4) OS 7
Hollander, P. etal [31] 2018 Hodgkin’s lymphoma 459 242/217 < 45: 68%; ≥45: 32% H&E NR I - IV 154.8 OS 8
Kereszres, K. etal [32] 2007 Hodgkin’s lymphoma 104 54/50 33 (12, 72) H&E 64/40 I - IV 110 (24, 214) OS, DFS 7
von Wasielewski, R. etal [33] 2000 Hodgkin’s lymphoma 1511 745/766 (15, 75) H&E 510/823 I - IV 120 OS 8
Enblad, G.etal [34] 1993 Hodgkin’s lymphoma 140 NR 45 (11, 94) H&E 26/114 I - IV 48 (20, 85) DFS 6
van Driel, W.J. etal [35] 1996 Cervical cancer 83 0/83 42.1 H&E NR I - IIA 44.6 (5, 108) OS, DFS 7
Bethwaite, P. B. etal [36] 1993 Cervical cancer 67 0/67 43.7 (25, 76) H&E 28/39 IB 62.4 (1, 93) OS 7
Flamm, J. etal [37] 1992 Bladder cancer 428 289/139 70.2 (29, 91) H&E 99/329 NR 84 OS 7
Iwasaki, K. etal [38] 1986 Gastric cancer 647 364/283 (22, 84) H&E 157/490 I - IV (8, 92) OS 7
Ono, Y. etal [39] 2002 Penile cancer 17 17/0 68 (36, 84) H&E 9/8 I - IV NR OS 6
  1. H&E haematoxilyn and eosin, EPX eosinophil peroxide, NR not reported